Gilead delivered healthy earnings as a result of the huge sales of its hepatitis C drug Solvaldi. David Nelson, Chief Strategist at Belpointe Asset Management believes the stock could continue to move higher. Even though insurers are pushing back about the price of the treatment, Gilead wants to recoup the cost of research to develop the drug. Plus, taking the drug for a one time treatment prevents more expensive consequences of not taking the drug, like liver disease.
Stocks in this video: